TABLE 1.

Federal Legislative and Administrative Efforts to Address Drug Pricing

Bill	House	Senate	Constrain Drug Price Inflation	Biosimilar Reform	Pharmacy Benefit Manager Reform	Patent Reform and Generic Entry Reform	Enhanced Negotiating Authority for Drug Prices	Reduced Out-of-Pocket Expenses for Patients	Address the Disconnect Between Drug Price and Value	Curb Systems That Reward Use of High-Priced Drugs
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars (ACCESS) Act	HR 4597	S 3466		X				X
Ensuring Access to Lower-Cost Medicines for Seniors Act	HR 4913			X		X		X		X
Lower Drug Costs Now Act	HR 3		X				X	X
Prescription Drug Pricing Reduction Act of 2019		S 2543	X		X			X		X
Lower Costs, More Cures Act of 2019	HR 19					X	X	X		X
C-THRU Act of 2019		S 476			X			X
Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019	HR 2113		X		X					X
Affordable Prescriptions for Patients Act of 2019		S 1416		X		X
CREATES Act of 2019	HR 965	S 340		X		X
Protecting Consumer Access to Generic Drugs Act of 2019	HR 1499			X		X
Preserve Access to Affordable Generics and Biosimilars Act	HR 2375	S 64		X		X
2016 CMS Proposed Rule	N/A								X	X
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs	N/A			X		X			X	X